Healthcare entity

RhodoLED

Technology

All 1 tracked stories fall under one category: market-trends. Ameluz is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window.

Last mentioned: Mar 19, 2026

Entity pulse

Recent coverage · RhodoLED

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about RhodoLED

All 1 tracked stories fall under one category: market-trends. Ameluz is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are less corroborated than the beat average, carrying 2 original sources each against 3 for the same window. Their average consequence score of 5 runs below the beat's 5.9 for that window. We currently track 1 Healthcare story that mention RhodoLED, all published on March 19, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering RhodoLED. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q4 2025 Earnings

    Both companies report year-end results showing strong commercial momentum and narrowing losses.

  2. Major Health Plan Contract

    DarioHealth signs a multi-year agreement with a top-five national US health insurer.

  3. Biofrontera Supply Chain Update

    Resolution of RhodoLED manufacturing bottlenecks, enabling faster lamp deployment.

  4. DarioHealth MSK Launch

    Full integration of musculoskeletal health modules into the core digital platform.

Stories mentioning RhodoLED 1

Market Trends Neutral

Biofrontera and DarioHealth Q4 Results Signal Shift Toward Commercial Scaling

Biofrontera and DarioHealth reported Q4 2025 earnings, highlighting a pivotal transition from clinical development to aggressive commercial scaling. While Biofrontera capitalizes on its dermatology market share with Ameluz, DarioHealth is demonstrating the viability of its multi-condition digital health platform through expanded B2B partnerships.

2 sources

Source: finance.yahoo.com · finance.yahoo.com

RhodoLED is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.